Karen Van Nuys

Sep 10, 2024 | jamanetwork.com | Dima M. Qato |Karen Van Nuys

Pharmacy benefit managers (PBMs) play an important role in financing and delivering prescription drugs for health insurers, including designing formularies and pharmacy networks, negotiating drug prices, and reimbursing pharmacies.1 Despite evidence that 3 PBMs (CVS Caremark, Express Scripts, and Optum Rx) accounted for 79% of prescriptions in the US in 20232 and growing concerns about the role of the highly concentrated PBM market on rising out-of-pocket costs and pharmacy closures,3,4...

Jul 22, 2024 | healthpolicy.usc.edu | Karen Van Nuys |Stephanie Hedt |Geoffrey F. Joyce |Darius Lakdawalla

Patients and consumers bear the costs of an inefficient pharmaceutical distribution system through higher costs at the pharmacy counter and reduced access to critical therapies. As policymakers consider reforms to the drug supply chain, they should keep five principles in mind to ensure better outcomes for patients.

Oct 14, 2023 | thehill.com | Neeraj Sood |Karen Van Nuys

Most Americans believe drugs cost too much and big pharma is to blame. That powerful political sentiment undergirds Medicare’s new authority to negotiate prices directly with manufacturers. The negotiations may result in lower revenues for pharma but will also imperil future drug development.  There is a better solution: Force transparency into the drug supply chain, unleashing market forces on middlemen whose hidden deals generate excessive profits.

Mar 28, 2023 | washingtonpost.com | Erin E. Trish |Karen Van Nuys

Comment on this storyCommentErin E. Trish is the co-director of the University of Southern California Schaeffer Center for Health Policy and Economics. Karen Van Nuys is the executive director of the Value of Life Sciences Innovation program at the Schaeffer Center. Even if they have health insurance, Americans routinely face surprisingly high charges at the pharmacy counter.

Mar 12, 2023 | inverse.com | Dana P. Goldman |Karen Van Nuys

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70 percent and capping insulin copays at US$35 for uninsured patients and those with private health insurance.